Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia
Rhea-AI Summary
Alkermes (ALKS) has launched Vibrance-3, a Phase 2 clinical study evaluating ALKS 2680 for idiopathic hypersomnia (IH). The study will assess the safety and efficacy of their novel oral selective orexin 2 receptor agonist versus placebo in adults with IH.
The randomized, double-blind trial will enroll approximately 96 patients across U.S., Australia, and Europe sites. Participants will receive one of three doses (10mg, 14mg, or 18mg) or placebo once-daily for eight weeks. The primary endpoint measures decrease in sleepiness using the Epworth Sleepiness Scale score.
This development follows encouraging Phase 1b data and addresses a significant unmet need, as over 90% of patients in a recent Sleep Consortium survey reported moderate to high impact of IH symptoms on their lives. IH affects an estimated 40,000 people in America.
Positive
- Expansion of clinical pipeline with Phase 2 trial initiation addressing 40,000-patient market
- Strong market opportunity supported by 90% of surveyed patients reporting moderate to high symptom impact
- Encouraging Phase 1b proof-of-concept data supporting further development
- Comprehensive development program with parallel trials for multiple sleep disorders
Negative
- Early-stage development with no guaranteed success
- Significant R&D expenses with multiple ongoing Phase 2 trials
- Small target market of only 40,000 patients in America
News Market Reaction
On the day this news was published, ALKS declined 1.48%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
"The initiation of Vibrance-3 represents an important step forward for the ALKS 2680 development program as we seek to advance a potential new treatment option for people living with idiopathic hypersomnia. There remains high unmet need for the idiopathic hypersomnia community, as evidenced by a recent survey conducted by the Sleep Consortium1 in which more than
Vibrance-3 is a phase 2, randomized, double-blind, dose-range-finding, placebo-controlled study evaluating the safety and efficacy of ALKS 2680 in adults with IH. Participants will be randomized to receive one of three doses of ALKS 2680 (10 mg, 14 mg or 18 mg) or placebo to be taken once-daily for eight weeks. The primary endpoint will assess, by dose level, whether participants taking ALKS 2680 experience a greater decrease in sleepiness compared to participants taking placebo alone, as measured by the change in Epworth Sleepiness Scale (ESS) score. Secondary endpoints include change in Idiopathic Hypersomnia Severity Scale (IHSS) score and incidence of adverse events. The study is expected to enroll approximately 96 patients with IH across sites in the
More information can be found at www.clinicaltrials.gov (identifier: NCT06843590) and www.vibrancestudies.com (for
Vibrance-1 and Vibrance-2, phase 2 studies evaluating the safety and efficacy of ALKS 2680 in adults with narcolepsy type 1 (NCT06358950) and narcolepsy type 2 (NCT06555783), respectively, are currently ongoing.
About ALKS 2680
ALKS 2680 is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Orexin, a neuropeptide produced in the lateral hypothalamus, is considered to be the master regulator of wakefulness due to its activation of multiple, downstream wake-promoting pathways that project widely throughout the brain.2 Targeting the orexin system may address excessive daytime sleepiness across hypersomnolence disorders, whether or not deficient orexin signaling is the underlying cause of disease.3 Once-daily oral administration of ALKS 2680 was previously evaluated in a phase 1 study in healthy volunteers and patients with NT1, NT2 and IH, and is currently being evaluated in the phase 2 Vibrance-1, Vibrance-2 and Vibrance-3 studies in patients with NT1, NT2 and IH, respectively.
About Idiopathic Hypersomnia
Idiopathic hypersomnia (IH) is a rare, chronic, neurological sleep disorder characterized by excessive daytime sleepiness despite normal sleep durations.4,5 Additional common symptoms can include severe sleep inertia (individuals may feel groggy or disoriented for prolonged periods after waking up), unrefreshing naps, fatigue and cognitive dysfunction.6,7 The underlying neuropathology of idiopathic hypersomnia is unknown.4 IH affects an estimated 40,000 people in America.8
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the potential therapeutic and commercial value of ALKS 2680 for the treatment of narcolepsy and idiopathic hypersomnia; and the company's expectations regarding clinical development activities for ALKS 2680. The company cautions that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether ALKS 2680 could be shown to be ineffective or unsafe; potential changes in the cost, scope and duration of the ALKS 2680 development program; whether preclinical and initial clinical results for ALKS 2680 will be predictive of results of future clinical studies or real-world results; whether future clinical studies or future stages of ongoing clinical studies for ALKS 2680 will be initiated or completed on time or at all; and those risks and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2024 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.
1 The Illuminate Hypersomnia "Voice of the Patient" Report. Contains data from 811 survey respondents conducted in spring 2024.
2 Buysse, D. Diagnosis and assessment of sleep and circadian rhythm disorders. Journal of Psychiatric Practice. 2005; 11(2):102-115
3 Ten-Blanco M, Flores A, Cristino L, Pereda-Perez I. Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies. Frontiers in Neuroendocrinology. 2023;69(101066). https://www.sciencedirect.com/science/article/pii/S0091302223000146
4 Trotti LM, Arnulf I. Idiopathic Hypersomnia and Other Hypersomnia Syndromes. Neurotherapeutics. 2021;18(1):20-31. doi:10.1007/s13311-020-00919-1
5 American Academy of Sleep Medicine. The International Classification of Sleep Disorders. Third Edition (ICSD-3). 2014.
6 Trotti LM. Waking up is the hardest thing I do all day: Sleep inertia and sleep drunkenness. Sleep Med Rev 2016.
7 Vernet C, Leu-Semenescu S, Buzare MA, Arnulf I. Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepiness. J Sleep Res. 2010;19:525–534
8 Acquavella et al., J Clin Sleep Med 16:1255 (2020)
Alkermes Contacts:
For Investors: Sandy Coombs, +1 781 609 6377
For Media: Gretchen Murphy, +1 781 609 6419
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-announces-initiation-of-vibrance-3-phase-2-study-evaluating-alks-2680-for-the-treatment-of-idiopathic-hypersomnia-302416347.html
SOURCE Alkermes plc
FAQ
What is the primary endpoint of the ALKS Vibrance-3 Phase 2 study for idiopathic hypersomnia?
How many patients will the ALKS Vibrance-3 trial enroll and what are the dosing levels?
What is ALKS 2680 and how does it work for idiopathic hypersomnia?
How many Americans are affected by idiopathic hypersomnia that ALKS 2680 aims to treat?
What other conditions is ALKS 2680 being developed to treat besides idiopathic hypersomnia?
